However, blockade of the A2A adenosine receptor may be counterproductive in GBM as the FDA-approved A2A adenosine receptor agonist lexiscan has been shown to increase BBB permeability in in vitro and in vivo models (Kim and Bynoe, 2015). Here, ADORA2A is linked to glioblastoma.